What is Strategy 21/21 plan?

Strategy 21/21 plan is the company's capital-raising plan, announced in 2024, to raise matching dollar amounts through equity and through fixed-income securities to add bitcoin, later expanded as the 42/42 plan.

Updated Oct 20, 2026

What the plan covers

The 21/21 plan is Strategy's own plan, published by the company and described on strategy.com and in its filings. The two numbers in the name refer to equal dollar targets, in billions, for equity on one side and fixed income on the other. Equity means common stock, mostly sold through ATM programs. Fixed income means convertible notes and, increasingly, preferred stock, the instruments now called digital credit. Strategy later announced a larger 42/42 plan with the same split.

How the two halves work together

Example with hypothetical numbers. A company raises $10 billion from common stock and $10 billion from notes and preferred. The common stock dilutes shareholders but carries no fixed cost. The notes and preferred add no shares at issue but carry interest and dividends. Used together, they let the issuer add bitcoin while managing both dilution and fixed obligations.

  • Targets, not obligations. A plan states intent; progress is reported in filings.
  • Digital credit is the fixed-income half. Strategy's preferred series were issued as part of this program.
  • Track progress at the source. Strategy reports sales under each program in its 8-Ks.

The history of each series is in Strategy preferred stocks history.

MetricValue
Bitcoin held850,363 BTC
Bitcoin holdings value$55.06B
Total debt$1.05B
Annual preferred obligations$1.76B
Annual obligations in bitcoin27,225 BTC
Bitcoin held ÷ annual obligations31.2 years
Latest USD Reserve disclosed$4.8B as of Aug 16, 2026
$MSTR coverage of its dividends, in dollars and in bitcoin

Source: Roxom market data feed, updated Nov 16, 2026, 16:23 UTC. Balance-sheet figures from issuer filings via the feed. A simple coverage lens, not a credit rating.

Frequently asked questions

The 21/21 plan is Strategy's capital-raising plan, announced in 2024, to raise matching dollar amounts through equity and through fixed-income securities to add bitcoin. The two numbers refer to equal dollar targets, in billions, for each side. Strategy later announced a larger 42/42 plan with the same split.

The 42/42 plan is the larger version of the 21/21 plan that Strategy announced later. It keeps the same split between equity on one side and fixed income on the other, with larger dollar targets. Strategy publishes the plan and reports progress under each program in its filings.

Fixed income means convertible notes and, increasingly, preferred stock, the instruments now called digital credit. Strategy's preferred series were issued as part of this program. The equity half is common stock, mostly sold through at-the-market programs that let the company sell shares gradually at market prices.

No. The plan states targets and intent, not obligations. Progress is reported in Strategy's filings, including the 8-Ks that list sales under each program, and those filings are the source to track how much has been raised on the equity side and on the fixed-income side.

The two halves have different costs. Common stock dilutes shareholders but carries no fixed cost. Notes and preferred stock add no shares at issue but carry interest and dividends. Used together, they let an issuer add bitcoin while managing both dilution and fixed obligations.

Roxom terminal

Every figure here, live.

  • Prices in BTC and USD
  • Live yields and dividend dates
  • Dividends in bitcoin for eligible holders

Follow digital credit in bitcoin.

Live prices, yields and dividend dates in BTC and USD are in the Roxom terminal. Eligible holders on Roxom receive dividends in bitcoin.

Roxom Learn is educational content, not investment, tax or legal advice. Dividend rates and terms are set by each issuer and can change; past performance does not predict future results. Figures marked as live come from the Roxom market data feed with the time shown. Roxom is not available to U.S. persons, and availability depends on your country of residence.